Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …

residual disease
bone marrow plasma cells
dexamethasone
residual tumor
isatuximab
  • 0 views
  • 16 Feb, 2024
  • 16 locations
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …

residual disease
bone marrow plasma cells
dexamethasone
residual tumor
isatuximab
  • 0 views
  • 12 Nov, 2020
  • 11 locations
NA-831 Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

critical illness
critically ill
cervical cap
electrocardiogram
dexamethasone
  • 0 views
  • 16 Feb, 2024
  • 30 locations
Randomised Evaluation of COVID-19 Therapy

RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.

lopinavir
colchicine
iv immunoglobulin
immunoglobulin
aspirin
  • 0 views
  • 05 Aug, 2020
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

refractory multiple myeloma
antibiotics
antibiotic therapy
hepatitis c
arginine
  • 0 views
  • 04 Dec, 2020
  • 13 locations
Dexamethasone for COVID-19 Related ARDS: a Multicenter Randomized Clinical Trial

After RECOVERY trial prepublication, low dose (6 mg QD for 10 days) dexamethasone was recommended as the usual care treatment for severe COVID-19. At this time only 3 patients had been included in the trial.

respiratory tract infection
shock
dexamethasone
inflammatory response
respiratory failure
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Carfilzomib Daratumumab Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce profound clinical responses. The investigators want to observe the effectiveness of the quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8 cycles of KRDd …

autologous hematopoietic stem cell transplant
bone marrow plasma cells
renal failure
dexamethasone
cell transplantation
  • 0 views
  • 16 Feb, 2024
  • 1 location
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

Cycles will be administered by central venous port. Premedication with dexamethasone is recommended on the day before treatment initiation. Cycles will be repeated every 21 days up to progression or unacceptable toxicity.

  • 0 views
  • 18 Dec, 2024
  • 4 locations
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor (PRIME)  

Cycles will be administered by central venous port. Premedication with dexamethasone is recommended on the day before treatment initiation. Cycles will be repeated every 21 days up to progression or unacceptable toxicity.

  • 0 views
  • 15 Apr, 2024
  • 1 location
A Study to Compare Different Ways of Steroid Administration After Total Knee Implantation

We are going to evaluate the difference between perioperative intravenous steroid supplementation, perioperative periarticular steroid supplementation, and standard anaesthesia protocols. We'll evaluate the outcome of patients with knee osteoarthritis who are undergoing Total Knee Arthroplasty to understand which of the three treatments give more benefits to the patient.

anesthesia
dexamethasone sodium phosphate
dexamethasone
total knee replacement
osteoarthritis
  • 0 views
  • 16 Feb, 2024
  • 1 location